Answers are grounded in this paper and cite their sources.
Randomized controlled trial found secukinumab fails to improve inflammation in adults with Graves’ orbitopathy, suggesting further research is needed.
Context Interleukin (IL) 17, a key pro-inflammatory cytokine, drives inflammation and fibrosis in Graves’ orbitopathy (GO), and elevated IL-17 and Th17 cells correlate with disease activity and severity. Objective The ORBIT study aimed to evaluate the efficacy and safety of secukinumab, an IL-17A inhibitor, in subjects with active, moderate-to-severe GO. Design Randomized, double-blind, placebo-controlled, parallel-group, multicenter trial Patients and methods Adults with active, moderate-to-severe, non-sight–threatening GO randomly (1:1) received secukinumab 300 mg or placebo subcutaneously over a 16-week double-blind treatment period, followed by an additional 16-week open-label treatment phase for proptosis non-responders. Safety parameters, thyroid-related hormones, and autoantibodies were also assessed. Primary endpoint Overall response of reduced clinical activity score (CAS) of ≥2 points and reduction of ≥2 mm in proptosis from baseline without worsening in the fellow eye at Week 16. Results Twenty-eight adult GO patients with a CAS ≥4 were enrolled (secukinumab, n=14; placebo, n=14). None in either the secukinumab or placebo group achieved an overall response at Weeks 16 and 32, respectively, when all patients received open-label secukinumab. No clinically meaningful changes were observed in ophthalmic symptoms and signs, proptosis, lid aperture, eye muscle motility, CAS, and health-related quality of life either at Week 16 or Week 32. No meaningful impact on serum levels of thyroid-related hormones and antibodies was observed. Secukinumab was well tolerated, with mostly mild adverse events. Neither treatment-induced study discontinuation nor new safety signals were registered. Conclusion Secukinumab did not show clinical efficacy versus placebo when treating patients with active, moderate-to-severe GO.
No takes yet. Share an insight, caveat, or question.
Wolf et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: